Literature DB >> 9217691

Primary progressive multiple sclerosis.

A J Thompson1, C H Polman, D H Miller, W I McDonald, B Brochet, X Filippi M Montalban, J De Sá.   

Abstract

Patients with multiple sclerosis who develop progressive disability from onset without relapses or remissions pose difficulties in diagnosis, monitoring of disease activity and treatment. There is a need to define the diagnostic criteria for this group more precisely and, in particular, to describe a comprehensive battery of investigations to exclude other conditions. The mechanisms underlying the development of disability and the role of MRI in monitoring disease activity in this clinical subgroup require elucidation, particularly in view of the lack of change on conventional imaging in the presence of continuing clinical deterioration. The prognosis is poor and there are currently no treatment trials for this form of the disease.

Entities:  

Mesh:

Year:  1997        PMID: 9217691     DOI: 10.1093/brain/120.6.1085

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  66 in total

1.  Neurology in practice: multiple sclerosis.

Authors:  G N Fuller; I Bone
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-12       Impact factor: 10.154

2.  Natural history of multiple sclerosis.

Authors:  G C Ebers
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-12       Impact factor: 10.154

3.  HLA-DR 15 is associated with female sex and younger age at diagnosis in multiple sclerosis.

Authors:  A E Hensiek; S J Sawcer; R Feakes; J Deans; A Mander; E Akesson; R Roxburgh; F Coraddu; S Smith; D A S Compston
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-02       Impact factor: 10.154

Review 4.  Immunologic therapy for relapsing-remitting multiple sclerosis.

Authors:  H J MacLean; M S Freedman
Journal:  Curr Neurol Neurosci Rep       Date:  2001-05       Impact factor: 5.081

5.  Mean diffusivity and fractional anisotropy histograms of patients with multiple sclerosis.

Authors:  M Cercignani; M Inglese; E Pagani; G Comi; M Filippi
Journal:  AJNR Am J Neuroradiol       Date:  2001-05       Impact factor: 3.825

6.  Identification of genetic loci controlling the characteristics and severity of brain and spinal cord lesions in experimental allergic encephalomyelitis.

Authors:  R J Butterfield; E P Blankenhorn; R J Roper; J F Zachary; R W Doerge; C Teuscher
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

Review 7.  Mechanisms regulating regional localization of inflammation during CNS autoimmunity.

Authors:  Emily Pierson; Sarah B Simmons; Luca Castelli; Joan M Goverman
Journal:  Immunol Rev       Date:  2012-07       Impact factor: 12.988

8.  Discriminant analysis of the cognitive performance profile of MS patients differentiates their clinical course.

Authors:  Jürgen A Kraus; Cathleen Schütze; Barbara Brokate; Beate Kröger; Günther Schwendemann; Helmut Hildebrandt
Journal:  J Neurol       Date:  2005-03-06       Impact factor: 4.849

Review 9.  Prognostic factors for multiple sclerosis: the importance of natural history studies.

Authors:  George C Ebers
Journal:  J Neurol       Date:  2005-09       Impact factor: 4.849

10.  Expression of beta2 adrenoreceptors on peripheral blood mononuclear cells in patients with primary and secondary progressive multiple sclerosis: a longitudinal six month study.

Authors:  Y Zoukos; T N Thomaides; D Kidd; M L Cuzner; A Thompson
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-02       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.